Mihaela Tevet1, Razvan Ionescu2, Cornel Dragan3, Anca Roxana Lupu3. 1. Department of Hematology, Colentina Clinical Hospital, Bucharest, Romania. 2. Department of Internal Medicine, Colentina Clinical Hospital, Bucharest, Romania. 3. Department of Hematology, Coltea Clinical Hospital, Bucharest, Romania.
Abstract
BACKGROUND: A number of studies showed that the JAK2 V617F mutation increases the thrombotic risk in patients with myeloproliferative disorders (MPN) while others did not reveal this correlation, and it is unknown whether inherited thrombophilia is an additive risk factor in mutated subjects. Our aim was to clarify the contribution of JAK2 V617F to a hypercoagulable state, as well as its interaction with other thrombophilic factors in patients with thrombosis and myeloproliferative disorders. METHOD: We studied 192 patients with myeloproliferative disorders, 90 with Essential thrombocytemia (ET), 42 with Polycythemia vera (PV) and 60 with Primary or idiopathic myelofibrosis (PMI). From these patients a subgroup of only 62 patients underwent laboratory screening for thrombophilia. RESULTS: The JAK2 V617F mutation was present in 62.8% patients with myeloproliferative disorders, 97.6% with PV, 54.5 % with ET and 53.44% patients with PMI. The mutated patients had a relative risk (RR) for thrombosis at any time of 2.94 in comparison with "wild-type" patients which was 0.93; in those patients having both the mutation and thrombophilia the RR was 3.56 (95% CI 2.41-7.34) compared to patients with neither the mutation nor thrombophilia, suggesting an additive interaction between the two risk factors. CONCLUSION: In patients with myeloproliferatives neoplasias, the thrombotic risk is higher in the JAK2 V617F-mutated subgroup and it is further increased by the presence of inherited thrombophilia (especially by the presence of mutated F V Leiden and lupus anticoagulant).
BACKGROUND: A number of studies showed that the JAK2 V617F mutation increases the thrombotic risk in patients with myeloproliferative disorders (MPN) while others did not reveal this correlation, and it is unknown whether inherited thrombophilia is an additive risk factor in mutated subjects. Our aim was to clarify the contribution of JAK2 V617F to a hypercoagulable state, as well as its interaction with other thrombophilic factors in patients with thrombosis and myeloproliferative disorders. METHOD: We studied 192 patients with myeloproliferative disorders, 90 with Essential thrombocytemia (ET), 42 with Polycythemia vera (PV) and 60 with Primary or idiopathic myelofibrosis (PMI). From these patients a subgroup of only 62 patients underwent laboratory screening for thrombophilia. RESULTS: The JAK2 V617F mutation was present in 62.8% patients with myeloproliferative disorders, 97.6% with PV, 54.5 % with ET and 53.44% patients with PMI. The mutated patients had a relative risk (RR) for thrombosis at any time of 2.94 in comparison with "wild-type" patients which was 0.93; in those patients having both the mutation and thrombophilia the RR was 3.56 (95% CI 2.41-7.34) compared to patients with neither the mutation nor thrombophilia, suggesting an additive interaction between the two risk factors. CONCLUSION: In patients with myeloproliferatives neoplasias, the thrombotic risk is higher in the JAK2 V617F-mutated subgroup and it is further increased by the presence of inherited thrombophilia (especially by the presence of mutated F V Leiden and lupus anticoagulant).
Authors: Marc A Rodger; Natasha Kekre; Grégoire Le Gal; Susan R Kahn; Philip S Wells; David A Anderson; Isabelle Chagnon; Sussan Solymoss; Mark Crowther; Arnaud Perrier; Richard White; Linda Vickars; Timothy Ramsay; Marisol T Betancourt; Michael J Kovacs Journal: Br J Haematol Date: 2011-04-26 Impact factor: 6.998
Authors: Camilla Nielsen; Henrik S Birgens; Børge G Nordestgaard; Lasse Kjaer; Stig E Bojesen Journal: Haematologica Date: 2010-12-15 Impact factor: 9.941
Authors: Animesh Pardanani; Terra L Lasho; Kebede Hussein; Susan M Schwager; Cristy M Finke; Rajiv K Pruthi; Ayalew Tefferi Journal: Mayo Clin Proc Date: 2008-04 Impact factor: 7.616
Authors: Ayalew Tefferi; Juergen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Tiziano Barbui; Curtis A Hanson; Giovanni Barosi; Srdan Verstovsek; Gunnar Birgegard; Ruben Mesa; John T Reilly; Heinz Gisslinger; Alessandro M Vannucchi; Francisco Cervantes; Guido Finazzi; Ronald Hoffman; D Gary Gilliland; Clara D Bloomfield; James W Vardiman Journal: Blood Date: 2007-05-08 Impact factor: 22.113
Authors: Alexandra P Wolanskyj; Susan M Schwager; Rebecca F McClure; Dirk R Larson; Ayalew Tefferi Journal: Mayo Clin Proc Date: 2006-02 Impact factor: 7.616
Authors: R Dambrauskienė; R Gerbutavičius; R Ugenskienė; R Jankauskaitė; A Savukaitytė; R Šimoliūnienė; M Rudžianskienė; R Gerbutavičienė; E Juozaitytė Journal: Balkan J Med Genet Date: 2017-06-30 Impact factor: 0.519